⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Continuous Manufacturing for Small Molecule APIs Industry Research 2026 - Global Market Size, Share, Trends, Opportunities, and Forecasts, 2021-2025 & 2026-2031
globenewswire.com
LLY
SNGX
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
prnewswire.com
SNGX
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
prnewswire.com
SNGX
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease
globenewswire.com
SNGX
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
globenewswire.com
SNGX
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
globenewswire.com
SNGX
AMGN
FOLD
CTOR
TNXP